Leadership

Robert Geho has more than twenty-five years of experience as an entrepreneurial business leader focused primarily on working with leading innovators in leading edge diabetes drug development. After being diagnosed with type 1 diabetes while in business school, he pivoted from undergraduate training as a classical musician to a career in the life sciences. Under his leadership, Diasome has advanced to a preeminent position in global insulin development, supported by prominent investors in type 1 and type 2 diabetes and by a who's who of internationally recognized clinical leaders in diabetes research.
 
Over the past two decades, Robert has formed and led teams that have achieved multiple firsts in diabetes research and development, including the first human trial of liver-targeted insulin, the first phase 2b oral insulin trial, and the first phase 2b liver targeted rapid acting insulin trial. These programs have made significant contributions to the field's understanding of restoring normal insulin physiology and glucose metabolism.
 
As both a patient and a life sciences professional, he combines experience in complex financing transactions, regulatory strategy, and drug development with deeply personal insights into the critical issues facing people with diabetes.
 
Robert received his undergraduate degree in a joint program from the Cleveland Institute of Music (CIM) and Case Western Reserve University (CWRU) and an MBA from CWRU. He currently serves as Vice-Chair of the Board at CIM and previously was a board member of The Diabetes Hands Foundation, one of the first global online advocacy organizations for people with diabetes.

Dr. Hobbs leads all aspects of Diasome’s clinical programs, guides the development strategy, and oversees interactions with global regulatory agencies, key thought leaders, policymakers, and professional associations.

His career includes over 20 years of progressive clinical and medical experience in the biopharmaceutical industry before joining Diasome, with various leadership roles at Novo Nordisk in medical affairs and 7 years serving as the Chief Medical Officer in North America.

His background includes over a decade of direct clinical experience, where his medical practice focused on the intensive management of people living with diabetes of all ages, and he served as chairman of the medicine department for a large regional medical center in Kentucky. He earned his medical degree from the University of Louisville School of Medicine and has completed focused executive training at the University of Pennsylvania’s Wharton School of Business.

Dr. Geho has spent his career in pharmaceutical research and development at both Fortune 100 and biotechnology companies.  As head of pharmaceutical research at the Procter & Gamble Company, he led the development of Didronel, the first approved bisphosphonate drug for treating bone disease, and Osteoscan, the first bone imaging agent.  In metabolism and endocrinology, Dr. Geho’s research has been published in leading journals over several decades, and he is recognized as a thought leader in the role of the liver in glucose metabolism and in the design of pharmaceutical systems to address dysregulation of glucose in the liver.  

He received his undergraduate degree in Chemistry from Bethany College (Bethany, West Virginia), and he was one of the United States’ first recipients of an NIH funded combined MD/PhD degree in Medicine and Pharmacology from Case Western Reserve University (Cleveland, Ohio).  During his doctoral training, his primary advisor and mentor was Nobel Laureate Earl Sutherland, MD, discoverer of the cyclic AMP second messenger system. Upon graduating from Medical School, he joined the School’s faculty in the Departments of Surgery and Pharmacology as one of the youngest instructors in the history of the University.

From 2011-2018, Dr. Geho served as co-chief translational officer of the CWRU School of Medicine and is currently an Adjunct Professor of Medicine at CWRU. Dr. Geho has over thirty-nine issued US Patents in the field of diabetes and targeted drug delivery.

Dr. Muchmore joined Diasome in 2016 and has led the execution of multiple HDV Insulin human clinical trials, including the Company’s ISLE-1 Phase 2b study of HDV Insulin in patients with Type 1 diabetes.  He has been a clinical consultant working almost exclusively in diabetes-related endeavors for the past four years.

Previously, Dr. Muchmore worked as a consulting endocrinologist at Scripps Clinic and Research Foundation. He received his medical degree from University of California San Diego School of Medicine. He has held and continues to hold numerous consulting and medical advisory roles for large pharmaceutical companies, including Eli Lilly, Halozyme Therapeutics and Kinexum Services.

Kent joined Diasome in 2020 as Vice President of Strategy & Commercial Development.

Prior to joining Diasome Kent led the development of the North American Health Practice at Marcus Thomas, a leading independent marketing consultancy. Prior to Marcus Thomas, Kent held numerous leadership positions focused on corporate strategy, business development, and brand strategy at WPP and flourish. Throughout his tenure Kent played key roles in commercial growth for Alkermes, BMS, Bayer and Zimmer Biomet.

Kent has completed advanced studies in Management, Strategy & Innovation at the MIT Sloan School of Management

Dr. Bode is an expert in diabetes at the Atlanta Diabetes Associates and is a clinical associate professor at Emory University in the Department of Medicine. He has served on the board of directors of the Atlanta chapters of the Juvenile Diabetes Research Foundation (JDRF) and the American Diabetes Association (ADA).

Bode serves on the board of directors of Glytec and is a member of the JDRF research team validating the efficacy and safety of real-time continuous glucose monitoring (CGMS).

Robert Geho has more than twenty-five years of experience as an entrepreneurial business leader focused primarily on working with leading innovators in leading edge diabetes drug development. After being diagnosed with type 1 diabetes while in business school, he pivoted from undergraduate training as a classical musician to a career in the life sciences. Under his leadership, Diasome has advanced to a preeminent position in global insulin development, supported by prominent investors in type 1 and type 2 diabetes and by a who's who of internationally recognized clinical leaders in diabetes research.
 
Over the past two decades, Robert has formed and led teams that have achieved multiple firsts in diabetes research and development, including the first human trial of liver-targeted insulin, the first phase 2b oral insulin trial, and the first phase 2b liver targeted rapid acting insulin trial. These programs have made significant contributions to the field's understanding of restoring normal insulin physiology and glucose metabolism.
 
As both a patient and a life sciences professional, he combines experience in complex financing transactions, regulatory strategy, and drug development with deeply personal insights into the critical issues facing people with diabetes.
 
Robert received his undergraduate degree in a joint program from the Cleveland Institute of Music (CIM) and Case Western Reserve University (CWRU) and an MBA from CWRU. He currently serves as Vice-Chair of the Board at CIM and previously was a board member of The Diabetes Hands Foundation, one of the first global online advocacy organizations for people with diabetes.

Dr. Geho has spent his career in pharmaceutical research and development at both Fortune 100 and biotechnology companies.  As head of pharmaceutical research at the Procter & Gamble Company, he led the development of Didronel, the first approved bisphosphonate drug for treating bone disease, and Osteoscan, the first bone imaging agent.  In metabolism and endocrinology, Dr. Geho’s research has been published in leading journals over several decades, and he is recognized as a thought leader in the role of the liver in glucose metabolism and in the design of pharmaceutical systems to address dysregulation of glucose in the liver.  

He received his undergraduate degree in Chemistry from Bethany College (Bethany, West Virginia), and he was one of the United States’ first recipients of an NIH funded combined MD/PhD degree in Medicine and Pharmacology from Case Western Reserve University (Cleveland, Ohio).  During his doctoral training, his primary advisor and mentor was Nobel Laureate Earl Sutherland, MD, discoverer of the cyclic AMP second messenger system. Upon graduating from Medical School, he joined the School’s faculty in the Departments of Surgery and Pharmacology as one of the youngest instructors in the history of the University.

From 2011-2018, Dr. Geho served as co-chief translational officer of the CWRU School of Medicine and is currently an Adjunct Professor of Medicine at CWRU. Dr. Geho has over thirty-nine issued US Patents in the field of diabetes and targeted drug delivery.

Frank McCaney is the Chairman of the Board of Directors at NMS Labs.  He is an accomplished executive with more than 25 years of demonstrated growth and success in medical devices and drug development.  Experienced in Business Management at the CEO level, drug development, raising capital, M&A, Sales and Marketing, and turnarounds.

Mr. McCaney previously served as CEO of Strata Skin Sciences (SSKN: NASDAQ) and before that he was CEO of Corpak MedSystems, a private equity-backed medical device company in the field of enteral feeding. Corpak was sold to Halyard Health (HYH: NYSE) for $174 million in May 2016. Prior to Corpak, he was the founder and CEO of Nitric BioTherapeutics, a venture backed-medical technology company from 2006 until 2012. Prior to Nitric Bio, he was a senior executive at Viasys Healthcare, Inc. (VAS: NYSE), a medical technology company focusing on respiratory, neurology, medical disposable and orthopedic products and had a lead role in spinning Viasys out of Thermo Electron Corporation (TMO: NYSE). While at Viasys, Mr. McCaney had several responsibilities including strategy, business development and investor relations. Frank is also the Chairman of the Board of Allevi Inc, a Tissue Bioprinting company located in Philadelphia.

Thomas McDonald is the founder of McDonald Partners in Cleveland, Ohio.
He served as President and CEO of Wayne Hummer Investments in Chicago from 2003-2005.  Here, Tom had total responsibility for the financial success of the company and was charged with growing the organization through the addition of high-quality financial advisors to service high net-worth clients of the parent company’s banks. 

Prior to joining Wayne Hummer, Tom spent 12 years with McDonald Investments in Cleveland.  He began as Director of Sales Development and progressed in responsibility to ultimately become Director of the Private Client Group.  In that capacity, Tom established the Investor Services Group and developed products and services dedicated to the affluent investor. 

In 1998, KeyBank bought McDonald Investments and Tom was responsible for integrating the Private Bank and Private Client Group.  He successfully integrated the organizations and was appointed to manage the Private Bank as well as the Private Client Group of McDonald Investments.  The combination allowed the firm to fully deliver all aspects the combined wealth management Key had to offer.  At the same time, Tom was responsible for growing the firm and increased revenues from just over $100 million to over $600 million – including Private Banking revenues.  Along with the revenue growth, Tom grew the number of financial advisors from 120 to over 600.  During his tenure at McDonald Investments, Tom served on various committees including McDonald Investments’ Board of Directors, the firm’s Capital Commitment Committee and the Compliance Committee.

Tom is actively involved in the industry through his participation in the Securities Industry Financial Markets Association, currently serving on the Board of Directors of SIFMA and serving as Chair of the Board’s Small Firms Committee.

In addition to industry involvement, he has been active in civic organizations during his career.  Currently he serves on the Board of Trustees of the MetroHealth System, the third largest health system in Northeast Ohio.  He has served on that Board since 2008 and served as its Chair from March of 2013 until March of 2019 and serves on a number of Metro’s Board committees.

Dr. Ordoñez has over 20 years of experience in the capital markets, sell-side and buy-side, in various roles including investment banking/advisory, equity research, merchant banking and venture capital. He is currently the Head of Investment Banking at Dominari Securities. Prior to it, he was a Senior Managing Director, Private Equity Investment Banking at Aegis Capital Corp. Before, he was a Managing Director, Head of Investment Banking Healthcare, at Ceros Capital Markets. Dr. Ordoñez specializes on deal origination, due diligence, corporate finance advisory and valuation modeling, syndication and deal execution. He is a member of the Board of Directors of various private companies.

Prior to this, Dr. Ordoñez was a Managing Director in Investment Banking at Noble. Prior to joining Noble, Dr. Ordoñez was the co-founder of Ciclofilin Pharmaceuticals, a startup biotech based in San Diego, CA. Dr Ordoñez has a Doctor in Medicine degree, and completed a Post-Doctoral Fellowship at the Karolinska Institute/Hospital in Stockholm, Sweden. He also obtained a Ph.D in Experimental Medicine and Biochemistry from McGill University. Dr Ordoñez has published on various topics in the areas of oncology, virology and immunology. Prior to founding Ciclofilin Pharma, Dr Ordoñez was Director of Healthcare Investments at Difference Capital, where he played a crucial role raising funds for various biotechnology/healthcare companies in North America

Peter Tollman is a Boston-based senior partner and managing director at The Boston Consulting Group which he joined in 1989. He leads BCG's People and Organization Practice in North America. Prior leadership roles have included global leadership of BCG's Biopharmaceutical's Sector and its R&D Topic. He holds a PhD in Engineering from the University of Cape Town South Africa and an MBA with distinction from Columbia Business School.

As one of BCG's most experienced client-service partners Peter has helped many of the world's leading corporations improve the competitiveness and performance of their organizations. His work has spanned the globe and involved a wide range of engagements including organization restructurings, governance redesigns, culture change, shareholder value and growth-enhancement initiatives, enterprise-wide transformations and coaching CEOs and other senior leaders through leadership transitions.

Eric Edidin formed Endo Ventures in 2013, soon after his then toddler daughter was diagnosed with diabetes. Endo was founded in response to a deficit of early-stage capital focused on companies impacting diabetes and other major global health problems.

Mr. Edidin is also president of Three B Holdings, a private family investment company, and co-founded Archer Capital Management an institutional asset management firm in 2006. Previously, he was a portfolio manager and co-head of credit investments at York Capital Management, a member of Morgan Stanley Capital Partners global private equity investment team and Blackstone Group’s restructuring advisory team. Mr. Edidin is an executive board member of the JDRF of Los Angeles, and member of the investment committee of the Jewish Communal Fund of NY and the Jewish Federation of Los Angeles.

Eric holds a B.B.A. degree with highest distinction from the University of Michigan, and an M.B.A from Harvard Business School.